cas 887581-47-7|| where to buy 6-chloro-3-(propan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione

Nom du produit:6-chloro-3-(propan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione

IUPAC Name:6-chloro-3-(propan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione

Unité d'emballage	Stock disponible	Prix($)
CM467305-100mg	in stock	ǵƄƄ
CM467305-250mg	in stock	ǊŢƓ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 887581-47-7 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:887581-47-7; Formule moléculaire:C7H9ClN2O2; Point de fusion:-; Code SMILES:CC(C)N1C(=O)NC(Cl)=CC1=O; Densité:

: Numéro de catalogue:CM467305; Poids moléculaire:188.61; Point d'ébullition:; N° Mdl:MFCD03001443; Stockage:

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Mavacamten; CAMZYOS(Mavacamten) was recently approved in the European Union, following its approval in the U.S. and other markets worldwide, and is the first and only cardiac myosin inhibitor approved to treat adult patients with symptomatic obstructive hypertrophic cardiomyopathy(HCM).
Mavacamten is a first-in-class, targeted inhibitor of cardiac myosin, reduces the number of myosin-actin cross-bridges and thus decreases excessive contractility characteristic of HCM.